DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages



Author: Steven Lamb MBChB, Dermatology Registrar, Waikato Hospital, Hamilton, New Zealand, 2000. Updated by Dr Darion Rowan, Dermatologist, Middlemore Hospital, Auckland, New Zealand; Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, 2004. 


What is imiquimod?

Imiquimod is an immune response modifier. It is manufactured as a 5% (50 mg/g) cream called Aldara™. Generic forms of imiquimod cream are also available. The Perrigo brand is funded by PHARMAC in New Zealand (2019).

A 3.75% cream called Zyclara™ has also been approved by the FDA in the USA but is not yet available in New Zealand (March 2017).

What is imiquimod used for?

Imiquimod is mainly used to treat:

It was first approved for use in genital warts. It may also be helpful in the unapproved treatment of common warts (once they have been thinned down by other means), plane warts, and herpes simplex. Experimentally it has been successful in reducing some keloid scars, granuloma annularevitiligomelanoma in situ (lentigo maligna type) and, in combination with diphencyprone, metastatic melanoma (see topical and intralesional immunotherapy for melanoma.

Although sometimes prescribed for molluscum contagiosum, clinical trials have not shown imiquimod to be of benefit, and it use for this indication is not recommended.

Before starting, a biopsy may be performed to confirm the diagnosis. Imiquimod is particularly useful for field changes, superficial skin cancers with poorly defined margins, and in areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs. 

How does imiquimod work?

Imiquimod works by stimulating the immune system to release a number of chemicals called cytokines, which are important in fighting viruses and destroying cancer cells.

When used to treat skin cancers and pre-cancerous lesions it results in inflammation, which destroys the lesion. The degree of inflammation is quite variable from person to person, in part due to the type of skin lesion and in part due to genetic factors. Imiquimod is taken up by ‘toll-like receptor 7’ on specific immune cells found in the epidermis; these receptors are expressed more in some individuals and in some skin lesions than in others.

Treatment regimes for imiquimod cream

Various imiquimod treatment regimes are used. For example:

  • Actinic keratoses: imiquimod is typically used two or three times weekly for four to six weeks, repeated if necessary after a break of four weeks. Very scaly lesions should be frozen with liquid nitrogen about three weeks before starting imiquimod.
  • Basal cell carcinomas and intraepidermal carcinoma: imiquimod is used five times weekly for six weeks. 
  • Genital warts: imiquimod is used three times weekly; or, if available, 3.75% cream daily; until total clearance or for up to 8 weeks.
  • (Off label) lentigo maligna: imiquimod is used three to seven times per week for six to 16 weeks. Close follow-up is essential.  

The imiquimod should be applied less often if the reaction is excessive, and more often if no reaction occurs (perhaps accompanied by a topical retinoid to enhance absorption of imiquimod into the skin). The course can be repeated, and treatment is sometimes continued for up to 16 weeks.

Treatment should be carefully monitored, because the cream may need to be applied more or less frequently than originally planned or for a shorter or longer course, depending on response. Once the inflammation has settled there is generally a good or excellent cosmetic result with little scarring. 

How to use imiquimod cream

The 5% product is supplied either as a box of sachets, each containing 250 mg, or as a pump-pack (2 g). Wash hands before and after applying imiquimod cream. 

Cut the top off the sachet or pierce the sachet with a needle and squeeze out a tiny amount of cream onto your fingertip. If using the pump pack, remove the protective cap and prime several times before pressing the pump once only to dispense the cream. Apply the cream to the affected areas.

Although the information on the packet states that the sachet is for single-use, some people seal it using a paper clip or tape and store it in a closed container to prevent the cream drying out.

Imiquimod is usually used during the winter months but, as it is not photosensitising, it may be used at any time of year. Sun protection with clothing and sunscreen can continue as usual.

Imiquimod in the genital area should be washed off before having sexual intercourse. It can weaken rubber condoms.

What to expect from imiquimod cream

Areas treated with imiquimod will become inflamed. The effects include itching, burning, redness, ulceration (sores), scabbing, flaking, and pain. These reactions indicate that the cream is likely to be effective - if there is no inflammation, imiquimod is unlikely to clear the lesion. An exaggerated response may clear the skin lesion sooner than expected — sometimes after as few as three or four applications. In some patients, surrounding untreated areas also become inflamed but this will settle when treatment is discontinued.

If black scabs and ulceration occur or there are severe systemic symptoms, the cream should be discontinued.

Effect of imiquimod

More images of the effect of imiquimod.

Side effects from imiquimod cream

When using imiquimod cream, 'flu-like symptoms may develop, such as fever, fatigue, headache, nausea, diarrhoea and muscle pain. These are generally mild and may be treated with paracetamol. Side effects should resolve within a few days of stopping treatment. They may also resolve with continuing treatment.

Imiquimod has been reported to cause drug-induced pemphigus, reactivate pre-existing pemphigus in remission as well as worsen other autoimmune diseases including rheumatoid arthritis. The use of topical imiquimod therefore in patients with a pre-existing autoimmune condition should be undertaken with caution.

Severe inflammation induced by imiquimod can result in drug-induced vitiligo.

New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.



  • Dahl MV. Imiquimod: An immune response modifier. J Am Acad Dermatol 2000; 43: S1–5. Medline
  • Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6–11. Medline
  • Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol 2000; 43: S12–17. Medline
  • Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25–30. Medline
  • Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002–7. Medline
  • Mackenzie-Wood A, de Launey J, Kossard S, et al. Safety and efficacy of imiquimod 5% cream for the treatment of Bowen's disease. J Invest Dermatol 1998; 110: 684 (abstract only).
  • Syed TA, Goswami J, Ahmadpour OA, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double blind study. J Dermatol 1998; 25: 309–13. Medline
  • Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–19. doi:10.1016/j.jid.2016.10.019 Journal
  • Tio DCKS, van Montfrans C, Ruijter CGH, Hoekzema R, Bekkenk MW. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. Acta Derm Venereol. 2019 Jun 24. doi: 10.2340/00015555-3241. [Epub ahead of print] PubMed PMID: 31233181. PubMed
  • Papanikolaou M, Lawrence CM. Long-term outcomes of imiquimod-treated lentigo maligna. Clin Exp Dermatol. 2019 Aug;44(6):631–6. doi: 10.1111/ced.13896.  PubMed PMID: 30663131. PubMed
  • Sebaratnam DF, Martin LK, Rubin AI, et al. Reversible relapse of pemphigus foliaceus triggered by topical imiquimod suggests that Toll-like receptor 7 inhibitors may be useful treatments for pemphigus. Clin Exp Dermatol. 2011;36(1):91–3. doi:10.1111/j.1365-2230.2010.03918.x PubMed
  • Zhong CS, Hasbun MT, Jones KM, Schmidt BAR, Hussain SH. Pemphigus-like eruption as a complication of molluscum contagiosum treatment with imiquimod in a 5-year-old girl. Pediatr Dermatol. 2020;37(2):379–80. doi:10.1111/pde.14115 PubMed

On DermNet

Other websites

Books about skin diseases


Related information

Sign up to the newsletter